

### Worldwide contacts for additional information

#### **World Headquarters**

Paul Weitz Director, Business Research Technology Catalysts International 605 Park Avenue Falls Church, VA 22046 U.S.A. Telephone: (703) 531-0242 Fax: (703) 237-7967 E-mail: pweitz@technology-catalysts.com Internet: www.technology-catalysts.com

#### Europe

Ms. Jana Kuhnlova Executive Managing Director INVENTIA s.r.o. Politickych veznu 7 110 00 Praha 1, Czech Republic Telephone: 420 2 2224 7484 Facsimile: 420 2 2421 8645 E-mail: kulnlova@inventia.cz Internet: www.inventia.cz

Graham L. Crawford, MSC Managing Director Technology Catalysts International UK Blacksmiths Clifton Road Newton Blossomville Bedford MK43 8AS, UK Telephone: 44 (0) 1234 881583 Facsimile: 44 (0) 1234 881027 E-mail: gcrawford@technology-catalysts.com

Dr. Gerhard Wallenwein Managing Director Laves Chemie Consulting Koenigsteiner Strasse 80 D-65812 Bad Soden, Germany Telephone: 49 (0) 6196 62057 Facsimile: 49 (0) 6196 27837 E-mail: laveschemie@t-online.de Internet: www.laveschemie.de

Dr. Karim Balan Technology Catalysts Germany Aubachweg 4 93055 Regensburg, Germany Telephone: 49 (0) 170 24 17 542 Facsimile: 49 (0) 941 706 06 58 E-mail: kbalan@web.de

#### South America

Carlos A. Massone, M.D. President Qualia S.A. Jeronimo Salguero 2533, Piso 12 "A" 1425, Buenos Aires, Argentina Telephone: 54 11 4807 3433 Facsimile: 54 11 4807 2933 E-mail: acrlos.massone@qualia.com.ar Internet: www.qualia.com.ar

© 2003 Technology Catalysts International

### Asia

Ken-ichi Itoh President, TCI Japan 2-46-4, Utsukushigaoka Aoba-ku, Yokohama 225-0002, Japan Telephone: 81 45 902 5304 Facsimile: 81 45 902 5476 E-mail: kenitol@ca.mbn.or.jp

Akio Fukui

Associate Director Sumika Technical Information Service Inc. 6-17,Koraibashi 4-chome Chuo-ku, Osaka 541-0033, Japan Telephone: 81 6 6220 3364 Facsimile: 81 6 6220 3361 E-mail: akio-fukui@ya.sumitomo-chem.co.jp

Ms. Katherine Song (Myung-Lim Song) Representative Director PHARMAX Research & Consulting, Inc. 5th Floor, Seoul Kangnam Building 727-16, Yoksam-2-dong Seoul, Korea Telephone: 82 2 761 9681 Facsimile: 82 2 761 9681 Facsimile: 820 g@pharmax.co.kr Internet: www.pharmax.co.kr

Dr. Satya Agarwala Chairman Agarwala & Associates 62 Ashoka Apartments 68 Napean Sea Road Mumbai 400 006, India Telephone: 91 22 2364 1543 Facsimile: 91 22 2364 1553 E-mail: satleela@hotmail.com

Daya K. Dhaon Managing Director Delhi Consulting Group Pvt. Ltd. C-512 Defence Golony New Delhi 110024, India Telephone: 91 11 2433 6130 91 11 2433 6442 Facsimile: 91 11 2462 5355 E-mail: dikdhaon@sity.com

Visit TCI s Home Page at: www.technologv-catalysts.com



# Business Opportunities in the Russian Pharmaceutical Market



## **ABOUT TCI**

echnology Catalysts International (TCI), founded in 1979, provides technology assessment, technology licensing, and competitive intelligence to various industries. With headquarters in Falls Church, VA, TCI has offices and affiliates in Germany, the UK, the Czech Republic, India, Korea, Japan, and Argentina.

Several specialized consulting services are offered with an orientation toward global strategic alliances in the pharmaceutical and fine chemical industries:

- Optically Active Chemical Information Service (OACIS)
- Drug Delivery Information Service (DDIS)
- Late-Stage Product Acquisition Service (LSPAS)
- Generic Drug Analysis Service (GxAS)
- Gene Therapy Information Service (GTIS)
- Licensing Locator
- Out-Licensing Services (OLS)

TCI also periodically publishes reports on topics of importance to the pharmaceutical industry such as:

- Biopharmaceutical Farming
- Anti-HIV and Related Pharmaceuticals
- Delivery of Poorly Soluble or Poorly Permeable Drugs
- Oral Fast-Dissolving Drug Delivery

# About INVENTIA s.r.o.

INVENTIA, affiliated with TCI, was founded in 1993 to provide technology transfer services for industrial companies. Emphasis is on health care, pharmaceuticals, polymers, chemical processing and fine chemicals. Services include:

- Consulting on matters related to technology transfer, licensing, scientific cooperation, and intellectual property.
- Complex agency services and consulting in chemical/pharmaceutical R&D, production and trade, with an emphasis on Central Europe, Russia, and the CIS territory.
- Special services such as market analyses and surveys, sourcing products, APIs, dossiers, distribution activities, and regulatory affairs.
- Representation of pharmaceutical companies in the Czech/Slovak Republics.
- Drafting and negotiating of license and scientific cooperation agreements.

**THE REPORT** 

The Russia that we know today can trace its recent history from 1985, when "perestroika" was declared. This signaled the shift from the state-dominated political and economic system of the USSR to the market-based economy of the Russian Federation. The change in the economic system, which includes the privatization of industry (excluding major energy organizations), is so dramatic that the transition has been very difficult for both the government as well as the Russian people. This transition is an on-going process and will continue for many years.

It is clear, however, that Russia has benefited from the shift to a market-based system. Recent GDP data for Russia indicate that growth in 2003 will be as much as 5 percent (due to higher oil prices). Expectations are for continued growth in 2004 and 2005 in the range of 4.2 to 4.5 percent.

The purpose of this report is to provide the reader with an analysis of the Russian pharmaceutical industry and identify potential business opportunities for companies in the developed regions of the world.

The report, prepared by TCI's affiliate in the Czech Republic, INVENTIA s.r.o., details the structure and dynamics of the Russian pharmaceutical industry as it stands today, and provides insight into why generics offer the greatest near-term opportunities.

In addition, the report identifies developments within Russia related to:

- Good Manufacturing Practice
- Certification of Medications
- Intellectual Property Protection
- Research and Development
- Imports
- Distribution
- Foreign and Domestic Investments

Further, useful contacts for companies seeking opportunities in the Russian pharmaceutical industry are provided.

• Full range of patenting and trademark services.

# TABLE OF CONTENTS

### 1. Introduction

- 2. Russian Pharmaceutical Market Overview
  - 2.1 General Characteristics of Russian Economy
  - 2.2 Characteristics and Main Features of Pharmaceutical Production in Various Federal Circles of Russia
    - 2.2.1 Concentration of Pharmaceutical Production in Individual Regions
    - 2.2.2 Shares of Individual Federal Circles in Total Retail Sales
  - 2.3 Best Selling Products According to ATC Groups
  - 2.4 Imports versus Domestic Production 2.4.1 Wholesale Prices
    - 2.4.2 Producer Prices
  - 2.5. Management and Control of Russian Pharmaceutical Market
    - 2.5.1 Good Manufacturing Practice
    - 2.5.2 Certification of Imported and Locally Manufactured Medications Impact on Drug Distribution
  - 2.6 Intellectual Property Protection
    - 2.6.1 Eurasian Patent Organization
    - 2.6.2 Rospatent
    - 2.6.3 Patent Law
    - 2.6.4 Information Sources
    - 2.6.5 Statistics

### 3. Research and Development

- 3.1 General Characteristics of R&D
- 3.2 R&D in Biotechnologies
- 3.3 Good Clinical Practice and Opportunities for Preclinical and Clinical Trials



- 4. Registration Procedure
- 5. Production
  - 5.1 General Characteristics of Russian Pharmaceutical Production
  - 5.2 Main Producers
- 6. Import
- 7. Distribution
  - 7.1 Characteristics of Russian Pharmaceutical Distribution Market
  - 7.2 Main Distributors
  - 7.3 Wholesale versus Retail
  - 7.4 Hospitals versus Pharmacies
  - 7.5 Associations of Wholesalers / Producers
  - 7.6 Pharmacies Network
- 8. Rx, OTC, Nutrition Supplements
- 9. Foreign Investments
  - 9.1 Production
    - 9.1.1 Packing of Final Products
    - 9.1.2 Greenfield Projects
    - 9.1.3 Joint-Ventures
  - 9.2 Distribution
  - 9.3 Retail
- 10. Domestic Investments
- 11. Conclusion
- 12. Useful Contacts
  - 12.1 Managing Authorities
  - 12.2 Producers
  - 12.3 Distributors
  - 12.4 R&D and Medical Institutes
- 13. References

### **Business Opportunities in the Russian Pharmaceutical Market** PURCHASE AGREEMENT

• • •

•

•

•

One Copy (PDF or Printed Version)\$3,950Extra Hard Copies\$300	License Fee for more than 5 users of PDF Version\$1,000
We agree to limit the circulation of this report to employees of our co corporation holds at least a 50 percent interest. Upon receipt of this signed Purchase Agreement, INVENTIA/Techn purchase amount, payable upon request.	
Name	
Title	
Company	
Address	
Telephone	Facsimile
Email	
Signature	Date
<ul> <li>Printed version (add \$35 for domestic shipping and \$45 fe</li> <li>PDF (Adobe® Acrobat, Portable Document Format)</li> <li>Total Amount Due:</li> <li>For credit card payment, please charge credit card:          <ul> <li>Master Card #</li> </ul> </li> </ul>	
For orders placed in Europe: Check enclosed, made payable to INVENTIA s.r.o. Should you wish to make a wire transfer, remit to:	For orders placed in the United States and other countries outside of Europe:
Please contact INVENTIA s.r.o. directly. Please invoice me/the company at the above address.	Check enclosed, made payable to Technology Catalysts International. Should you wish to make a wire transfer: Please contact TCI directly for account information. Please invoice me/the company at the above address.